Update on IGF-1 as a diagnostic tool for acromegaly by Reusch, C
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Update on IGF-1 as a diagnostic tool for acromegaly
Reusch, C
Reusch, C (2010). Update on IGF-1 as a diagnostic tool for acromegaly. In: British Small Animal Veterinary
Association - BSAVA Congress, Birmingham, 08 April 2010 - 11 April 2010.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
British Small Animal Veterinary Association - BSAVA Congress, Birmingham, 08 April 2010 - 11 April 2010.
Reusch, C (2010). Update on IGF-1 as a diagnostic tool for acromegaly. In: British Small Animal Veterinary
Association - BSAVA Congress, Birmingham, 08 April 2010 - 11 April 2010.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
British Small Animal Veterinary Association - BSAVA Congress, Birmingham, 08 April 2010 - 11 April 2010.
Update on IGF-1 as a diagnostic tool for acromegaly  
Claudia E. Reusch, DVM, Professor, DiplECVIM-CA 
Clinic for Small Animal Internal Medicine, Winterthurerstrasse 260, 8057 Zurich 
 
Acromegaly in cats is caused by a growth hormone (GH) secreting tumor in the anterior lobe of the 
pituitary gland. Unlike in dogs increased levels of progesterone do not induce the diseases in cats. 
The vast majority of acromegalic cats are also suffering from diabetes mellitus, which is triggered by 
GH-related insulin resistance. Typical clinical signs are therefore associated with poorly regulated 
diabetes and include polyuria, polydipsia and polyphagia. Additionally, the cats may show increase in 
body weight and size (head, paws), organomegaly, proganthia inferior and potentially neurological 
signs if the pituitary tumor is large. In some cats clinical signs are severe, raising the suspicion of 
acromegaly already at the time of diagnosis of diabetes. However, in a substantial number of cats 
“anabolic” signs (e.g. increase in body weight and size, prognathia inferior) are subtle. In those cases 
acromegaly may easily be overlooked or only considered after realizing that regulation of diabetes is 
difficult.  
Results of routine laboratory investigation (hematology and chemistry profile) are consistent with 
poorly regulated diabetes and therefore of no particular help. The diagnosis of acromegaly requires 
demonstration of GH excess and/or increased levels of insulin-like growth factor 1 (IGF-1).  
Several constraints are associated with the measurement of GH, such as limited availability of assays 
validated for the cat, need to ship frozen samples and last but not least the pulsatile nature of GH 
secretion. Due to the latter a single basal GH measurement may normal and the diagnosis therefore 
be missed. Conversely, an increased GH level may be the result of a secretory pulse and may 
occasionally be seen in a normal cat. Repeated sampling at 10-minutes intervals or GH measurement 
during glucose tolerance test or octreotide test may be helpful, however so far very limited data about 
the diagnostic accuracy are available.  
Measurement of IGF-1 is a good alternative to GH determination.  
IGF-1 is a small, single-chain polypeptide, which has much structural homology with proinsulin. The 
plasma concentration of IGF-1 is mainly regulated by 1) GH, which stimulates IGF-1 synthesis in the 
liver and other tissues, 2) insulin, which either directly regulates the GH receptor or has a permissive 
effect on post-GH receptor events, 3) nutrients, which reduce IGF-1 when restricted and 4) binding 
proteins, which may affect IGF-1 bioavailability when their concentrations are abnormal. IGF-1 values 
are relatively constant throughout the day and no freezing of samples is required for shipping. 
Studies in humans with untreated or poorly controlled type 1 diabetes mellitus have revealed that IGF-
1 concentrations are frequently low, which is explained by the fact that adequate insulin 
concentrations in the portal vein are required for expression and function of GH receptors on 
hepatocytes and that this mechanism is impaired in insulin-deficient states. In human patients with 
type 2 diabetes mellitus IGF-1 levels are dependent on the degree of metabolic control, with near 
normal IGF-1 levels in well-controlled diabetics, whereas IGF-1 levels tend to decrease in poorly 
controlled individuals. It has also been suggested, that the degree to which IGF-1 is decreased in type 
2 diabetics reflects the degree of beta-cell impairment e.g. insulin secretory capacity. IGF-1 
concentrations are restored in a time-dependent manner after starting insulin therapy in humans and 
normalization continues during the first month after the start of insulin therapy. We recently showed 
that the situation is similar in cats. In newly diagnosed diabetic cats IGF-1 was significantly lower than 
the concentration in healthy control cats. IGF-1 increased significantly when insulin treatment was 
started and was not different from levels in controls after 1 – 2 months. During treatment the 
concentration of IGF-1 was independent of the quality of glycemic control.  
Another aim of the study was to determine whether IGF-1 concentrations are high in diabetic cats with 
acromegaly before they are treated with insulin or whether they are low, as in the cats without 
acromegaly. Since in most cats diabetes is diagnosed first and acromegaly is only suspected when it 
proves difficult to achieve glycemic control the number of cases was small. Five of 7 diabetic cats with 
acromegaly had previously been treated with insulin and their IGF-1 levels were high. However, in the 
2 previously untreated diabetic cats with acromegaly IGF-1 was low resp. in the low normal range. 
After initiating insulin therapy IGF-1 levels increased markedly. Although the findings need to be 
substantiated by a larger number of cats it appears reasonable to postpone IGF-1 measurement in 
newly diagnosed diabetic cats for at least one month after initiating insulin therapy. In the majority of 
diabetic cats with acromegaly reported so far, IGF-1 levels were measured only after a certain period 
of insulin therapy and have been found to be increased. A few years ago one group of investigators 
reported that high IGF-1 may occur in diabetic cats without acromegaly. These findings resulted in 
uncertainty about the diagnostic suitability of the IGF-1 test in the veterinary community. The result 
was difficult to explain since high IGF-1 levels have never been reported in human diabetics and they 
contrasted the results of our study mentioned above. It is important to realise that the conflicting 
results may be due to technical differences. Circulating IGF-1 is nearly completely bound to proteins 
which interfere with the immunoassays and may induce high or low IGF-1 levels; for this reason the 
binding proteins must be removed before the assay is performed. Acid size exclusion chromatography 
is considered as the „gold standard method“ for removal (and was the method used in our study). 
Since it is time- and labour intensive other methods, such as acidification, acid-ethanol extraction, 
displacement assays are more often used. However, removal of the binding proteins may not be 
equally effective. We therefore compared different methods and found variable performance. 
Significantly higher IGF-1 levels were found when an assay was used which included acid-ethanol 
extraction for the removal of the binding proteins. Five of 39 healthy cats had IGF-1 levels > 1000 
ng/dl which is usually considered the cut-off value for the diagnosis of acromegaly. Careful 
consideration of the assay is therefore crucially important.  
Pituitary radiation is an effective treatment modality for cats with acromegaly resulting in improved 
diabetic control in the majority of cases. However, this improvement does not go along with a fall in 
IGF-1; which is therefore not considered a suitable marker to reflect clinical improvement.  
In summary measurement of IGF-1 levels is helpful to screen diabetic cats for the presence of 
acromegaly. It should be noted that IGF-1 may be unreliable (i.e. low) in newly diagnosed diabetic cats 
with acromegaly, therefore measurement is best performed after 1 – 2 months of insulin therapy. 
Performance of IGF-1 assays vary and false positive results may occur in some of them, most likely 
due to incomplete removal of IGF-1 binding proteins.   
